Monitor for Form 144 filings or future clusters to determine if this is part of a larger divestment trend. Given the small size relative to market cap and CEO's history of structured trades, this is likely routine.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 6 $475.52entry
- T+1 · 8mo ago +10.70%α +9.85% · $526.40
- T+5 · 8mo ago +12.71%α +14.24% · $535.95
- T+20 · 8mo ago +16.94%α +18.98% · $556.07
- T+60 · 6mo ago +14.53%α +1.75% · $544.62
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
United Therapeutics CEO Martine Rothblatt sold 1,156 shares in two open-market transactions totaling $616,635 over the past week, while also exercising options for 19,000 shares at a mix of $0 and $146.03 strike prices. The sales represent a small fraction of market cap and are likely part of pre-arranged trading plans or tax-related activity following option exercises.
Key Financial Metrics
Key Facts
- CEO Martine Rothblatt sold 1,156 shares in open-market transactions for $616,635 over two days.
- Concurrent with the sales, Rothblatt exercised 19,000 derivative securities, including 9,500 shares at $0 (likely RSU vesting) and 9,500 at $146.03 (in-the-money options).
- Total open-market sale value: $616,635, approximately 0.0026% of $23.5B market cap.
- All transactions occurred within a 5-day window, suggesting coordinated activity likely tied to option exercise and tax obligations.
Financial Impact
$616,635 in open-market sales; $1.39M in derivative exercises (non-cash)
Risk Factors
- Perception of insider selling could weigh on sentiment if misinterpreted.
- Future larger-scale selling may signal reduced confidence, though current activity is not indicative.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (4 trades, 7d window) | cluster-UTHR-1773664262597 |
Track record
123 reports on UTHR
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry price pending
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers